| Literature DB >> 25965070 |
Meng Liu1, Rui Fan1, Xinhua Liu1, Feng Cheng2, Ju Wang1.
Abstract
Nicotine is the addictive substance in tobacco and it has a broad impact on both the central and peripheral nervous systems. Over the past decades, an increasing number of genes potentially involved in nicotine addiction have been identified by different technical approaches. However, the molecular mechanisms underlying nicotine addiction remain largely unclear. Under such situation, a comprehensive analysis focusing on the overall functional characteristics of these genes, as well as how they interact with each other will provide us valuable information to understand nicotine addiction. In this study, we presented a systematic analysis on nicotine addiction-related genes to identify the major underlying biological themes. Functional analysis revealed that biological processes and biochemical pathways related to neurodevelopment, immune system and metabolism were significantly enriched in the nicotine addiction-related genes. By extracting the nicotine addiction-specific subnetwork, a number of novel genes associated with addiction were identified. Moreover, we constructed a schematic molecular network for nicotine addiction via integrating the pathways and network, providing an intuitional view to understand the development of nicotine addiction. Pathway and network analysis indicated that the biological processes related to nicotine addiction were complex. Results from our work may have important implications for understanding the molecular mechanism underlying nicotine addiction.Entities:
Mesh:
Year: 2015 PMID: 25965070 PMCID: PMC4429103 DOI: 10.1371/journal.pone.0127438
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Gene Ontology terms enriched in nicotine addiction-related genes (NAGenes).
| GO Terms | No. of genes | P-value | PBH-value | |
|---|---|---|---|---|
|
| ||||
| GO:0007268 | synaptic transmission | 67 | 3.07×10–39 | 1.21×10–36 |
| GO:0007267 | cell-cell signaling | 83 | 3.85×10–39 | 1.21×10–36 |
| GO:0019226 | transmission of nerve impulse | 70 | 6.75×10–39 | 1.69×10–36 |
| GO:0035637 | multicellular organismal signaling | 70 | 2.80×10–38 | 5.86×10–36 |
| GO:0050877 | neurological system process | 82 | 2.06×10–34 | 3.23×10–32 |
| GO:0043279 | response to alkaloid | 25 | 2.11×10–25 | 1.89×10–23 |
| GO:0014070 | response to organic cyclic compound | 50 | 2.74×10–25 | 2.29×10–23 |
| GO:0042493 | response to drug | 41 | 8.02×10–25 | 6.29×10–23 |
| GO:0097305 | response to alcohol | 23 | 2.64×10–21 | 1.18×10–19 |
| GO:0031644 | regulation of neurological system process | 30 | 4.13×10–21 | 1.79×10–19 |
| GO:0050890 | cognition | 27 | 9.03×10–21 | 3.78×10–19 |
| GO:0007611 | learning or memory | 26 | 1.36×10–20 | 5.51×10–19 |
| GO:0035094 | response to nicotine | 15 | 3.61×10–20 | 1.42×10–18 |
| GO:0023061 | signal release | 35 | 4.76×10–20 | 1.76×10–18 |
| GO:0015837 | amine transport | 21 | 5.68×10–20 | 2.04×10–18 |
| GO:0042417 | dopamine metabolic process | 14 | 9.05×10–20 | 3.15×10–18 |
| GO:0051952 | regulation of amine transport | 18 | 9.50×10–20 | 3.22×10–18 |
| GO:0051969 | regulation of transmission of nerve impulse | 28 | 1.14×10–19 | 3.76×10–18 |
| GO:0050804 | regulation of synaptic transmission | 27 | 1.20×10–19 | 3.86×10–18 |
| GO:0044057 | regulation of system process | 39 | 1.28×10–19 | 4.02×10–18 |
|
| ||||
| GO:0030594 | neurotransmitter receptor activity | 25 | 8.57×10–29 | 1.36×10–26 |
| GO:0004889 | acetylcholine-activated cation-selective channel activity | 14 | 6.47×10–25 | 5.14×10–23 |
| GO:0005230 | extracellular ligand-gated ion channel activity | 22 | 4.94×10–24 | 2.62×10–22 |
| GO:0005231 | excitatory extracellular ligand-gated ion channel activity | 19 | 1.49×10–23 | 5.12×10–22 |
| GO:0015464 | acetylcholine receptor activity | 14 | 1.61×10–23 | 5.12×10–22 |
| GO:0015276 | ligand-gated ion channel activity | 24 | 5.08×10–20 | 1.15×10–18 |
| GO:0022839 | ion gated channel activity | 30 | 1.62×10–17 | 2.58×10–16 |
| GO:0038023 | signaling receptor activity | 60 | 3.29×10–17 | 4.76×10–16 |
| GO:0042166 | acetylcholine binding | 10 | 5.34×10–17 | 7.08×10–16 |
| GO:0005261 | cation channel activity | 27 | 7.74×10–16 | 6.48×10–15 |
| GO:0022838 | substrate-specific channel activity | 32 | 2.30×10–15 | 1.83×10–14 |
| GO:0004888 | transmembrane signaling receptor activity | 53 | 3.11×10–14 | 2.06×10–13 |
| GO:0035240 | dopamine binding | 8 | 4.89×10–14 | 3.11×10–13 |
| GO:0015075 | ion transmembrane transporter activity | 38 | 9.12×10–12 | 5.58×10–11 |
| GO:0008324 | cation transmembrane transporter activity | 32 | 9.86×10–12 | 5.81×10–11 |
| GO:0022891 | substrate-specific transmembrane transporter activity | 38 | 7.70×10–11 | 4.22×10–10 |
| GO:0004952 | dopamine receptor activity | 5 | 4.67×10–10 | 2.40×10–9 |
| GO:0004497 | monooxygenase activity | 13 | 4.86×10–10 | 2.41×10–9 |
| GO:0016705 | oxidoreductase activity, acting on paired donors, withincorporation or reduction of molecular oxygen | 16 | 8.54×10–10 | 4.11×10–9 |
| GO:0008227 | G-protein coupled amine receptor activity | 9 | 3.52×10–9 | 1.65×10–8 |
| GO:0031406 | carboxylic acid binding | 16 | 1.16×10–8 | 5.12×10–8 |
| GO:0016597 | amino acid binding | 12 | 1.69×10–8 | 7.26×10–8 |
| GO:0035254 | glutamate receptor binding | 7 | 3.26×10–8 | 1.36×10–7 |
| GO:0005506 | iron ion binding | 13 | 5.60×10–7 | 2.23×10–6 |
|
| ||||
| GO:0097060 | synaptic membrane | 35 | 7.51×10–29 | 5.18×10–27 |
| GO:0045211 | postsynaptic membrane | 32 | 2.29×10–27 | 1.05×10–25 |
| GO:0043005 | neuron projection | 50 | 1.96×10–25 | 4.51×10–24 |
| GO:0005887 | integral to plasma membrane | 65 | 2.72 ×10–24 | 5.36×10–23 |
| GO:0031226 | intrinsic to plasma membrane | 65 | 1.92×10–23 | 3.31×10–22 |
| GO:0005892 | acetylcholine-gated channel complex | 13 | 8.13×10–23 | 1.25×10–21 |
| GO:0030424 | axon | 33 | 2.57×10–22 | 3.55×10–21 |
| GO:0043235 | receptor complex | 25 | 7.89×10–20 | 9.07×10–19 |
| GO:0030054 | cell junction | 43 | 2.51×10–17 | 2.48×10–16 |
| GO:0030425 | dendrite | 30 | 1.58×10–16 | 1.36×10–15 |
| GO:0033267 | axon part | 20 | 3.63×10–16 | 2.95×10–15 |
| GO:0044306 | neuron projection terminus | 16 | 1.11×10–15 | 8.51×10–15 |
| GO:0043679 | axon terminus | 15 | 5.22×10–15 | 3.43×10–14 |
| GO:0043025 | neuronal cell body | 26 | 5.04×10–15 | 3.43×10–14 |
| GO:0043197 | dendritic spine | 16 | 1.86×10–10 | 9.87×10–10 |
| GO:0044309 | neuron spine | 16 | 1.86×10–10 | 9.87×10–10 |
| GO:0042734 | presynaptic membrane | 10 | 1.54×10–9 | 7.59×10–9 |
| GO:0016023 | cytoplasmic membrane-bounded vesicle | 30 | 4.81×10–7 | 2.07×10–6 |
| GO:0008328 | ionotropic glutamate receptor complex | 6 | 1.43×10–6 | 5.80×10–6 |
| GO:0044327 | dendritic spine head | 10 | 2.19×10–6 | 8.17×10–6 |
| GO:0014069 | postsynaptic density | 10 | 2.19×10–6 | 8.17×10–6 |
a. Only GO terms with hierarchical level≥4 and containing 5 or more nicotine addiction-related genes are shown.
b. Number of genes in the 220 nicotine addiction-related genes and also in the category
c. P-value were calculated by hypergeometric test
d. PBH-value were adjusted by Benjamini & Hochberg (BH) method
Pathways enriched in nicotine addiction-related genes (NAGenes) (top 20 pathways).
| Canonical Pathways | P-value | PBH-value | NAGenes included in the pathway |
|---|---|---|---|
| cAMP-mediated signaling | 6.31×10–17 | 2.00×10–14 | ADRA2A, ADRB2, AGTR1, AKAP13, CAMK4, CHRM1, CHRM2, CHRM5, CNR1, CREB1, DRD1, DRD2, DRD3, DRD4, DRD5, GABBR1, GABBR2, GNAS, GRM7, HTR1F, HTR6, NPY1R, OPRM1, PDE4D, RAPGEF3 |
| Calcium Signaling | 1.00×10–15 | 2.00×10–13 | CAMK4, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNG, CREB1, GRIK1, GRIN2A, GRIN2B, GRIN3A, ITPR2, TRPC7 |
| G-Protein Coupled Receptor Signaling | 2.51×10–15 | 3.16×10–13 | ADRA2A, ADRB2, AGTR1, CAMK4, CHRM1, CHRM2, CHRM5, CNR1, CREB1, DRD1, DRD2, DRD3, DRD4, DRD5, GABBR1, GABBR2, GNAS, GRM7, HTR1F, HTR2A, HTR6, NPY1R, OPRM1, PDE4D, RAPGEF3 |
| Dopamine Receptor Signaling | 3.16×10–14 | 2.51×10–12 | COMT, DRD1, DRD2, DRD3, DRD4, DRD5, GNAS, MAOA, MAOB, NCS1, PPP1R1B, PPP2R2B, SLC18A2, SLC6A3, TH |
| Xenobiotic Metabolism Signaling | 2.00×10–12 | 1.41×10–10 | ABCB1, AHR, CAMK4, CYP1A1, CYP2B6, FMO1, GSTM1, GSTM3, GSTP1, GSTT1, IL6, MAOA, MAOB, MAP3K4, MGMT, NOS2, NQO1, PPP2R2B, SOD3, SULT1A1, TNF, UGT1A9, UGT2B10 |
| Dopamine-DARPP32 Feedback in cAMP Signaling | 2.69×10–10 | 1.45×10–8 | CAMK4, CREB1, DRD1, DRD2, DRD3GRIN3A, DRD4, DRD5, GNAS, GRIN2A, GRIN2B, ITPR2, KCNJ6, PPP1R1B, PPP2R2B, PRKG1 |
| Aryl Hydrocarbon Receptor Signaling | 2.88×10–10 | 1.45×10–8 | AHR, CCND1, CHEK2, CYP1A1, ESR1, GSTM1, GSTM3, GSTP1, GSTT1, IL6, MDM2, NQO1, TGFB1, TNF, TP53 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 4.37×10–10 | 1.78×10–8 | ABCB1, ABCC4, APOE, CD14, CETP, CYP2A6, CYP2B6, FMO1, GSTM1, GSTM3, GSTP1, GSTT1, MAOA, MAOB, MGMT, SOD3, SULT1A1, TNF |
| Gαi Signaling | 4.57×10–10 | 1.78×10–8 | ADRA2A, AGTR1, CHRM2, CNR1, DRD2, DRD3, DRD4, GABBR1, GABBR2, GNAS, GRM7, HTR1F, NPY1R, OPRM1 |
| Superpathway of Melatonin Degradation | 3.72×10–9 | 1.32×10–7 | CYP1A1, CYP2A6, CYP2B6, CYP2D6, MAOA, MAOB, MPO, SULT1A1, UGT1A9, UGT2B10 |
| Serotonin Receptor Signaling | 6.17×10–9 | 1.95×10–7 | HTR2A, HTR6, MAOA, MAOB, SLC18A2, SLC6A4, TPH1, TPH2 |
| eNOS Signaling | 1.17×10–8 | 3.39×10–7 | CAMK4, CHRNA10, CHRNA3, CHRNA4, CHRNA5, CHRNB1, CHRNB4, ESR1, GNAS, HSPA4, ITPR2, NOS3, PRKG1 |
| Glucocorticoid Receptor Signaling | 3.89×10–8 | 1.05×10–6 | ADRB2, CCNH, CREB1, ERCC2, ESR1, HSPA4, ICAM1, IFNG, IL13, IL6, IL8, NOS2, NPPA, NR3C1, PTGS2, TGFB1, TNF |
| Glutamate Receptor Signaling | 5.13×10–8 | 1.29×10–6 | CAMK4, DLG4, GRIK1, GRIK2, GRIN2A, GRIN2B, GRIN3A, GRM7, SLC1A2 |
| Neuropathic Pain Signaling In Dorsal Horn Neurons | 5.50×10–7 | 1.29×10–5 | BDNF, CAMK4, CREB1, GRIN2A, GRIN2B, GRIN3A, GRM7, ITPR2, KCNQ3, NTRK2 |
| AMPK Signaling | 1.10×10–6 | 2.40×10–5 | ADRA2A, ADRB2, CHRNA10, CHRNA3, CHRNA4, CHRNA5, CHRNB1, CHRNB4, GNAS, NOS3, PPP2R2B |
| Hepatic Cholestasis | 1.58×10–6 | 3.09×10–5 | ABCB1, CD14, CETP, ESR1, GNAS, IFNG, IL6, IL8, MAP3K4, SLCO3A1, TNF |
| Gαs Signaling | 1.58×10–6 | 3.09×10–5 | ADRB2, CHRM1, CHRM5, CNR1, CREB1, DRD1, DRD5, GNAS, HTR6, RAPGEF3 |
| GABA Receptor Signaling | 1.95×10–6 | 3.47×10–5 | DNM1, GABARAP, GABBR1, GABBR2, GABRA2, GABRA4, GABRE |
| PXR/RXR Activation | 2.00×10–6 | 3.47×10–5 | ABCB1, CYP2A6, CYP2B6, GSTM1, IL6, NR3C1, TNF, UGT1A9 |
a P-value were calculated by Fisher’s exact test
b PBH-value were adjusted by Benjamini & Hochberg (BH) method
c 220 nicotine addiction-related genes included in the pathway
Fig 1Pathway crosstalk among NAGenes-enriched pathways.
Nodes represent pathways and edges represent crosstalk between pathways. Node size corresponds to the number of NAGenes found in the corresponding pathway. Node color corresponds to the PBH-value of the corresponding pathway. Darker color indicates lower PBH-value. Edge width corresponds to the score of the related pathways. Node shape indicates pathway categories, with ellipse for neurodevelopment, diamond for immune, triangle for metabolism, square for other pathways.
Fig 2Nicotine addiction-specific network.
Ellipse nodes are NAGenes and triangular nodes are non-NAGenes. Node color corresponds to its degree in the human PPI network. Darker color indicates higher degree.
Genes included in the NA-specific network but not of NAGenes.
| Gene symbol | Gene name |
|---|---|
| ADIPOQ | Adiponectin |
| APOA1 | Apolipoprotein A-I |
| APP | Amyloid beta (A4) precursor protein |
| B3GNT1 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 |
| BAG6 | BCL2-associated athanogene 6 |
| CALM2 | Calmodulin 2 |
| CANX | Calnexin |
| CASK | Calcium/calmodulin-dependent serine protein kinase |
| CAV1 | Caveolin 1 |
| CFTR | Cystic fibrosis transmembrane conductance regulator |
| COL4A3 | Collagen, type IV, alpha 3 |
| CTSH | Cathepsin H |
| CYB5A | Cytochrome b5 type A |
| EEF1A1 | Eukaryotic translation elongation factor 1 alpha 1 |
| ELAVL1 | ELAV like RNA binding protein 1 |
| FBLN5 | Fibulin 5 |
| FLNA | Filamin A, alpha |
| GNA15 | Guanine nucleotide binding protein (G protein), alpha 15 (Gq class) |
| GPRASP1 | G protein-coupled receptor associated sorting protein 1 |
| GRB2 | Growth factor receptor-bound protein 2 |
| GSTO1 | Glutathione S-transferase omega 1 |
| IL4R | Interleukin 4 receptor |
| IL6ST | Interleukin 6 signal transducer |
| ITPR3 | Inositol 1,4,5-trisphosphate receptor, type 3 |
| LSM8 | LSM8 homolog, U6 small nuclear RNA associated |
| MAPK14 | Mitogen-activated protein kinase 14 |
| MMS19 | MMS19 nucleotide excision repair homolog |
| NFKB2 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 |
| NRP1 | Neuropilin 1 |
| NUP98 | Nucleoporin 98kDa |
| PAXIP1 | PAX interacting (with transcription-activation domain) protein 1 |
| PDZD3 | PDZ domain containing 3 |
| POLR2J | Polymerase (RNA) II (DNA directed) polypeptide J |
| PPP1CA | Protein phosphatase 1, catalytic subunit,alpha isozyme |
| PRADC1 | Protease-associated domain containing 1 |
| PRKCZ | Protein kinase C, zeta |
| SPP1 | Secreted phosphoprotein 1 |
| SPRY2 | Sprouty homolog 2 |
| TRAF3IP1 | TNF receptor-associated factor 3 interacting protein 1 |
| TTC8 | Tetratricopeptide repeat domain 8 |
| UBC | Ubiquitin C |
| YWHAE | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon |
| YWHAZ | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
| ZDHHC17 | Zinc finger, DHHC-type containing 17 |
Fig 3Molecular network for nicotine addiction.
This network is constructed based on the nicotine addiction-related pathways or pathway crosstalk identified in our study, NA-specific network and literature survey. NAGenes are highlighted in red while neurotransmitters are represented as pink ellipse. The enriched pathways are highlighted in yellow background.